Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 338 followers
Latest posts
Last updated about 3 hours ago
Lilly preps for ph. 2 launch after Verve gene editor cuts cholesterol on par with PCSK9 inhibitors
about 3 hours ago
Eli Lilly is laying the groundwork for a phase 2 trial of...
BioAge CEO talks NLRP3 and ‘pipeline in a pill’ ambitions
3 days ago
Recorded at Fierce Biotech Week in Boston, this episode of “The Top...
Has Novartis’ T-Charge been overtaken by in vivo CAR-Ts? Execs argue there’s room for both
3 days ago
It’s been more than four years since Novartis shook up the CAR-T...
OSE turns up the heat on ovarian cancer with phase 2, Keytruda-supported win
3 days ago
OSE Immunotherapeutics has shared phase 2 data on its neo-epitope vaccine candidate...
Biogen axes Denali-partnered Parkinson’s prospect after phase 2 flop
3 days ago
A phase 2b trial of Biogen and Denali Therapeutics’ Parkinson’s disease candidate...
Chutes & Ladders—Former FDA leader takes new biotech Turn
4 days ago
Stephen Hahn, M.D., who served as the commissioner of the FDA for...
ASCO: Merck, Kelun's sac-TMT ADC combo beats Keytruda by 65% on progression in first-line lung cancer
4 days ago
According to an abstract released ahead of the ASCO 2026 annual meeting...
Medtronic inks $650M deal for SPR Therapeutics
4 days ago
Medtronic has entered a deal to acquire SPR Therapeutics, a Cleveland-based company...
Betting on biotech: Prediction markets set sights on clinical trials
4 days ago
Several biotech contracts are rotating through Kalshi and Polymarket, while a recently...
Lilly’s triple-G drug helps patients lose roughly a quarter of weight, showcasing competitive profile
4 days ago
As Eli Lilly looks to hold its lead in the lucrative obesity...
Struggling Liminatus pays $320M in stock for CAR-T biotech InnocsAI
4 days ago
Cancer immunotherapy company Liminatus Pharma has agreed to pay out shares worth...
Infex, following in Insmed’s footsteps, advances lung disease candidate after clearing phase 2a
4 days ago
Infex Therapeutics is pushing ahead with development of a non-cystic fibrosis bronchiectasis...